Outlook Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in trillions USD

Scroll to see more
Outlook Therapeutics, Inc. income statement - Annual data in trillions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
Revenue & Gross Profit
Revenue1.410.000.000.000.000.000.000.00
Cost of Revenue1.360.000.000.000.000.000.000.00
Gross Profit0.060.000.000.000.000.000.000.00
Operating Expenses
Research & Development27.180.000.000.000.000.000.000.00
Selling, General & Administrative39.940.000.000.000.000.000.000.00
Operating Expenses67.120.000.000.000.000.000.000.00
Operating Income0.000.000.000.000.000.000.000.00
Other Income/Expense
Interest Income0.000.000.000.000.000.000.000.00
Interest Expense0.000.000.000.000.000.000.000.00
Other Income/Expense0.000.000.000.000.000.000.000.00
Income
Income Before Tax0.000.000.000.000.000.000.000.00
Income Tax Expense0.000.000.000.000.000.000.000.00
Net Income0.000.000.000.000.000.000.000.00
Net Income - Continuous Operations0.000.000.000.000.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA0.000.000.000.000.000.000.000.00
EBIT0.000.000.000.000.000.000.000.00
Depreciation & Amortization0.000.000.000.000.000.000.000.00
Earnings Per Share
Basic EPS-2.00-4.00-5.00-6.00-7.00-13.00--10.00
Diluted EPS-2.00-4.00-5.00-6.00-7.00-13.00-2.00-10.00
Basic Shares Outstanding0.000.000.000.000.000.000.000.00
Diluted Shares Outstanding0.000.000.000.000.000.000.000.00